Table 1.
Patients’ characteristics
| Characteristic | All | NLR change |
p-value | |
|---|---|---|---|---|
| ≤1.61 | >1.61 | |||
| Gender | 0.476 | |||
| Male | 56 (84.8) | 36 (81.8) | 20 (90.9) | |
| Female | 10 (15.2) | 8 (18.2) | 2 (9.1) | |
| Age (yr) | 0.066 | |||
| ≤65 | 36 (54.5) | 28 (63.6) | 8 (36.4) | |
| >65 | 30 (45.5) | 16 (36.4) | 14 (63.6) | |
| Stage | 0.927 | |||
| IIIA | 23 (34.8) | 16 (36.4) | 7 (31.8) | |
| IIIB | 43 (65.2) | 28 (63.6) | 15 (68.2) | |
| T stage | 0.654 | |||
| T0–2 | 25 (37.9) | 18 (40.9) | 7 (31.8) | |
| T3–4 | 41 (62.1) | 26 (59.1) | 15 (68.2) | |
| N stage | 0.692 | |||
| N0–1 | 6 (9.1) | 5 (11.3) | 1 (4.5) | |
| N2 | 26 (39.4) | 16 (36.4) | 10 (45.5) | |
| N3 | 34 (51.5) | 23 (52.3) | 11 (50.0) | |
| Smoking history | 0.737 | |||
| No | 12 (18.2) | 9 (20.5) | 3 (13.6) | |
| Yes | 54 (81.8) | 35 (79.5) | 19 (86.4) | |
| ECOG performance status | 0.815 | |||
| 0 | 28 (42.5) | 20 (45.5) | 8 (36.4) | |
| 1 | 35 (53.0) | 22 (50.0) | 13 (59.1) | |
| 2 | 3 (4.5) | 2 (4.5) | 1 (4.5) | |
| Pathology | 0.915 | |||
| Squamous cell carcinoma | 33 (50.0) | 21 (47.7) | 12 (54.6) | |
| Adenocarcinoma | 29 (43.9) | 20 (45.5) | 9 (40.9) | |
| Others | 4 (6.1) | 3 (6.8) | 1 (4.5) | |
| Chemotherapy regimen | 0.738 | |||
| Paclitaxel/carboplatin | 37 (56.1) | 23 (52.3) | 14 (63.7) | |
| Docetaxel/cisplatin | 26 (39.4) | 19 (43.2) | 7 (31.8) | |
| Others | 3 (4.5) | 2 (4.5) | 1 (4.5) | |
| Radiation dose (cGy) | 6,600 (5,200–7,260) | 6,600 (6,000–7,260) | 6,600 (5,200–7,000) | 0.035 |
| PTV volume (mL) | 430 (119–1,050) | 384 (119–964) | 488 (275–1,050) | 0.024 |
| Pre-CCRT NLR | 2.7 (1.03–16.03) | 2.7 (1.03–16.03) | 2.2 (1.09–4.46) | 0.176 |
| Pre-CCRT PLR | 145.5 (75.0–453.0) | 160 (75–453) | 132.5 (85–257) | 0.165 |
| Post-CCRT NLR | 3.0 (0.74–44.62) | 2.4 (0.74–7.23) | 6.0 (2.63–44.62) | <0.001 |
| Post-CCRT PLR | 172.5 (38–898) | 148.5 (38–379) | 265.5 (99–898) | <0.001 |
| NLR change | 1.2 (0.05–11.02) | 0.8 (0.05–1.61) | 2.5 (1.65–11.02) | <0.001 |
| PLR change | 1.1 (0.33–7.18) | 0.9 (0.33–1.9) | 1.9 (0.91–7.18) | <0.001 |
| CRP (mg/dL) | 0.9 (0.02–11.51) | 0.9 (0.02–10.66) | 1.1 (0.08–11.51) | 0.663 |
| ESR (mm/hr) | 43 (2–120) | 40.0 (2–120) | 47.5 (4–120) | 0.647 |
| LDH (U/L) | 419 (213–855) | 426 (213–855) | 396 (282–603) | 0.973 |
Values are presented as number (%) or median (range).
ECOG, Eastern Cooperative Oncology Group; PTV, planning target volume; CCRT, concurrent chemoradiotherapy; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; NLR change, dividing the post-CCRT NLR by the pre-CCRT NLR; PLR change, dividing the post-CCRT PLR by the pre-CCRT PLR; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; LDH, lactate dehydrogenase.